Literature DB >> 22899290

Activity and complexes of mTOR in diffuse large B-cell lymphomas--a tissue microarray study.

Anna Sebestyén1, Tamás B Sticz, Agnes Márk, Melinda Hajdu, Botond Timár, Karolina Nemes, Noémi Nagy, Zsófia Váradi, László Kopper.   

Abstract

Diffuse large B-cell lymphoma is a heterogeneous group of diseases with different responses to therapy. Targeting mTOR (mammalian target of rapamycin) offers a new approach to improve the treatment. mTOR inhibitors are being developed and are in clinical use in mantle cell lymphoma therapy and clinical trials are ongoing in other high-grade lymphomas as well. However, there is limited data about mTOR activity and the expression of its different complexes in diffuse large B-cell lymphomas. Tissue microarray blocks were constructed from paraffin-embedded biopsy specimens. More than 700 immunohistochemical stainings (mTOR signaling-related proteins and phosphoproteins, markers for lymphoma classification) were evaluated from 68 diffuse large B-cell lymphoma biopsies from conventionally treated and followed patients. Approximately 30% of cases were characterized as germinal center-derived diffuse large B-cell lymphomas, which showed virtually no mTOR activity, as determined by phospho-ribosomal S6 expression, the most sensitive marker of mTOR activity. In about 80% of non-germinal center-derived diffuse large B-cell lymphoma cases, positivity of mTOR-related phosphoproteins was observed, denoting mTOR activity. Moreover, Rictor (a characteristic protein of the mTOR complex2) was overexpressed in 43% of all diffuse large B-cell lymphomas and in 63% of mTOR-active non-germinal center diffuse large B-cell lymphoma samples. Rictor overexpression with mTOR activity indicated significantly worse survival for patients than mTOR inactivity or mTOR activity with low Rictor expression. These results suggest that mTOR activity is characteristic in most non-germinal center-derived diffuse large B-cell lymphomas with potentially variable mTOR-inhibitor sensitivity. Taken together, mTOR inhibitors may be useful in addition to regular therapy in diffuse large B-cell lymphomas, however, patient and inhibitor selection criteria must be carefully considered.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22899290     DOI: 10.1038/modpathol.2012.141

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  10 in total

1.  Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma.

Authors:  Jeffrey A Barnes; Eric Jacobsen; Yang Feng; Arnold Freedman; Ephraim P Hochberg; Ann S LaCasce; Philippe Armand; Robin Joyce; Aliyah R Sohani; Scott J Rodig; Donna Neuberg; David C Fisher; Jeremy S Abramson
Journal:  Haematologica       Date:  2012-11-09       Impact factor: 9.941

Review 2.  The role of metabolic ecosystem in cancer progression - metabolic plasticity and mTOR hyperactivity in tumor tissues.

Authors:  Anna Sebestyén; Titanilla Dankó; Dániel Sztankovics; Dorottya Moldvai; Regina Raffay; Catherine Cervi; Ildikó Krencz; Viktória Zsiros; András Jeney; Gábor Petővári
Journal:  Cancer Metastasis Rev       Date:  2022-01-14       Impact factor: 9.264

3.  mTOR pathway as a potential target in a subset of human medulloblastoma.

Authors:  Tímea Pócza; Anna Sebestyén; Eszter Turányi; Tibor Krenács; Agnes Márk; Tamás Béla Sticz; Zsuzsanna Jakab; Péter Hauser
Journal:  Pathol Oncol Res       Date:  2014-04-16       Impact factor: 3.201

4.  The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.

Authors:  Hajnalka Rajnai; Fenna H Heyning; Lianne Koens; Anna Sebestyén; Hajnalka Andrikovics; Pancras C W Hogendoorn; András Matolcsy; Ágota Szepesi
Journal:  Virchows Arch       Date:  2013-12-04       Impact factor: 4.064

5.  mTOR activity in AIDS-related diffuse large B-cell lymphoma.

Authors:  Sara H Browne; Julio A Diaz-Perez; Michael Preziosi; Charles C King; George A Jones; Sonia Jain; Xiaoying Sun; Erin G Reid; Scott VandenBerg; Huan-You Wang
Journal:  PLoS One       Date:  2017-02-13       Impact factor: 3.240

Review 6.  Modulation of mTORC1 Signaling Pathway by HIV-1.

Authors:  Burkitkan Akbay; Anna Shmakova; Yegor Vassetzky; Svetlana Dokudovskaya
Journal:  Cells       Date:  2020-04-28       Impact factor: 6.600

7.  HIV-1 Tat Activates Akt/mTORC1 Pathway and AICDA Expression by Downregulating Its Transcriptional Inhibitors in B Cells.

Authors:  Burkitkan Akbay; Diego Germini; Amangeldy K Bissenbaev; Yana R Musinova; Evgeny V Sheval; Yegor Vassetzky; Svetlana Dokudovskaya
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

8.  Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.

Authors:  Ágnes Márk; Melinda Hajdu; Zsófia Váradi; Tamás Béla Sticz; Noémi Nagy; Judit Csomor; Lajos Berczi; Viktória Varga; Monika Csóka; László Kopper; Anna Sebestyén
Journal:  BMC Cancer       Date:  2013-05-22       Impact factor: 4.430

9.  Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL).

Authors:  Karolina Nemes; Anna Sebestyén; Agnes Márk; Melinda Hajdu; István Kenessey; Tamás Sticz; Eszter Nagy; Gábor Barna; Zsófia Váradi; Gábor Kovács; László Kopper; Monika Csóka
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

10.  A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma.

Authors:  E Horvilleur; T Sbarrato; K Hill; R V Spriggs; M Screen; P J Goodrem; K Sawicka; L C Chaplin; C Touriol; G Packham; K N Potter; S Dirnhofer; A Tzankov; M J S Dyer; M Bushell; M MacFarlane; A E Willis
Journal:  Leukemia       Date:  2013-10-18       Impact factor: 11.528

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.